– USA, CA – Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Dr. Gaurav Aggarwal (M.D.) to its Board as an Independent Director.
“Gaurav brings extensive strategic leadership to Geron, and we believe his demonstrated track record in both corporate strategy and capital formation will add tremendous value as we look forward to a potential commercial launch in 2024,” said Chairman and CEO, Dr. John Scarlett.
About Dr. Gaurav Aggarwal
Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level.
“Geron’s tremendous science, expertise, clinical results and readiness to bring their first-in-class investigational telomerase inhibitor to the market have made this a very exciting time to join the Board,” said Dr. Gaurav Aggarwal. “I look forward to partnering with my fellow Board members and Geron’s leadership team to work to maximize the value of the Company and support its mission to enhance the lives of patients with hematologic malignancies.”
Dr. Aggarwal most recently served as Managing Director of Vivo Capital LLC, a global investment firm from 2016 to 2023, and CIO of its US public investment fund, from 2021 to 2023. Previously, he served as CBO of Ocera Therapeutics, Inc., a publicly traded clinical-stage company developing therapies for orphan liver conditions, from April 2014 through October 2016; as Managing Director of Investor Growth Capital from January 2013 through December 2013; and as a General Partner at Panorama Capital, L.P., a venture capital fund, from August 2006 through December 2012. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co.
Dr. Aggarwal has served on the board of directors of Unicycive Therapeutics Inc. since March 2023 and previously served on the boards of directors of Sierra Oncology, Inc., Hyperion Therapeutics, Inc., and several privately held biopharmaceutical companies.
Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.
About Geron
Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes, who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration with a Prescription Drug User Fee Act target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis.
SOURCE: https://www.geron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
